drug induced early menopause in breast cancer. Post-artificial-menopause syndrome
Conditions
Interventions
Intervention 1: Advising of oral paroxetine 7.5 mg daily for 6 weeks in control group. Intervention 2: Stellate ganglion block under sonographic guidance with 10 ml of 0.5% bupivacaine in study group.
Treatment - Drugs
Treatment - Other
Advising of oral paroxetine 7.5 mg daily for 6 weeks in control group
Stellate ganglion block under sonographic guidance with 10 ml of 0.5% bupivacaine in study group
Sponsors
Vice chancellor of Research- Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
21 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: symptoms suffering for a minimum period of one month, age 21 to 45 y/o, and life expectancy greater than 6 month. Exclusion criteria: patients under treatment with chemotherapy drugs, androgens, estrogens, progesterone analogs, or other known treatments of menopausal symptoms for example vitamin E, antidepressants and gabapentin, coagulation abnormalities, aspirin users, acute infections, cardiac diseases and ASA class =3.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hot flashes. Timepoint: before intervention and 2, 4 and 6 weeks after interventin. Method of measurement: Sloan and coworkers raing scale.;Sleep quality. Timepoint: before intervention and 2, 4 and 6 weeks after interventin. Method of measurement: The Pittsburgh Sleep Quality Index (PSQI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehzad Ebrahimi MD
Iran University of Medical Sciences
Outcome results
None listed